Twenty-four patients with acute promyelocytic leukemia were reviewed. Group I, treated between July 1970 and September 1973, received arabinosylcytosine and 6-thioguanine, and there was one complete remission, with 4 7 dying during induction with intracerebral hemorrhages, and 217 dying within one m
Acute promyelocytic leukemia. Therapy results and prognostic factors
✍ Scribed by Miguel A. Sanz; Isidro Jarque; Guillermo Martín; Ignacio Lorenzo; Jesús Martínez; Javier Rafecas; Emilio Pastor; María José Sayas; Guillermo Sanz; Federico Gomis
- Book ID
- 102669329
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 582 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
34 patients with acute promyelocytic leukemia (APL) were treated with daunorubicin (DNR) alone and simultaneous supportive therapy with low-dose heparin, platelet transfusions, and fresh frozen plasma. Two consecutive maintenance therapy regimens were employed in patients who achieved complete remission (CR): (I) a classical maintenance with methotrexate and 6-mercaptopurine, with DNR plus methyl-GAG reinductions; (2) from 1982 an intensive sequential combination therapy regimen was administered. CR was achieved in 23 patients (68%). Only one patient had leukemic resistance. Other failures were a consequence of postchemotherapy complications. A multivariate logistic regression analysis has been performed to evaluate the prognostic importance on response to remission induction of 25 patient and disease characteristics at diagnosis. The significant variables in decreasing order of significance were: serum albumin level, fever at diagnosis, serum creatinine level, and age. The median duration of remission and survival by Kaplan-Meier analysis were projected to be 24 and 25 months, respectively. Relapses occurred in 11 of 23 CR patients. Nine patients remained in the first remission from 5+ to 37+ months. Short-term (CR) and long-term results (duration of remission and survival) in APL treated for induction with DNR alone were similar to those obtained in other subtypes of acute myeloblastic leukemia by intensive combination chemotherapy.
C ~n ~~r 6 1 : 7 -1 3 , 1988.
📜 SIMILAR VOLUMES
To the Editor: Translocation t(9;22)(q34;q11) is found in 1-2% of newly diagnosed patients with de novo AML. The prognosis of Ph þ AML is very poor with a median survival time of only 7 months. We present two patients with de novo Ph þ AML who received induction chemotherapy and post-remission imati
Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia characterized by the morphology of the blast cells (M3 type in the FAB nomenclature), and a specific t(15;17) translocation. APL was further characterized by a specific sensitivity to all-trans retinoic acid's differentiation e